News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cempra Pharmaceuticals, Inc.'s Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity


4/4/2014 7:45:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW®) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES